The startup develops bio-better pharmaceuticals using advanced antibody design and production technologies to enhance existing treatments for oncology and immunological diseases. By focusing on four specific therapeutic targets, the company aims to provide patients with more effective formulations that address limitations of current marketed products.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current biologic therapies, while effective, can be limited by safety concerns, efficacy, cost-of-goods, and patient access. Many patients are unable to benefit fully from existing treatments due to these limitations.
Solution
Prana Biosciences develops "bio-betters," improved versions of already-approved biologic drugs, specifically monoclonal antibodies (mAbs), for oncology, autoimmunity, and infectious diseases. By leveraging advanced antibody design and production technologies, Prana aims to create biologics with superior safety and efficacy profiles, reduced manufacturing costs, and expanded patient populations. Their approach focuses on validated therapeutic targets with proven biology, resulting in bio-betters that offer enhanced tolerability, less frequent dosing, and improved clinical outcomes. Prana's operations model includes on-shore presence to mitigate supply chain risks.
Target Audience
The primary target audience includes patients with cancer, autoimmune disorders, and infectious diseases, as well as healthcare providers seeking more effective and accessible biologic therapies.
Features
- Utilizes state-of-the-art antibody design for improved therapeutic properties.
- Focuses on intercellular delivery of therapeutic modalities.
- Employs a robust and scalable biotherapeutic production engine.
- Conducts novel antibody isolation and characterization.
- Performs biologics CMC (Chemistry, Manufacturing, and Controls) development, including MCB (Master Cell Bank) creation and characterization, process development, and process characterization.
- Offers assay development for binding and functional characterization, including ELISA, Western blotting, Immunoprecipitation, Immunofluorescence, and Immunohistochemistry.
- Provides cell-based assays for viability, apoptosis, necrosis, migration/mobilization, chemotaxis, proliferation, differentiation, and internalization.